143 results about "Viral antigens" patented technology

The invention belongs to the field of virus detection and diagnosis, and relates to an anti-AAV2 monoclonal antibody as well as a preparation method and application thereof. The invention provides an anti-AAV2 rabbit monoclonal antibody, and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-AAV2 rabbit monoclonal antibody. The anti-AAV2 rabbit monoclonal antibody provided by the invention can be specifically combined with the VLP of AAV2, and can be used for detecting the AAV virus antigen. The anti-AAV2 monoclonal antibody provided by the invention provides an effective detection tool for the detection of AAV2 in the research and development process of a gene therapy vector and the detection of AAV2 in basic scientific research.

The invention discloses a self-presenting antigen-ligand fusion protein, a vaccine containing the fusion protein and application of the self-presenting antigen-ligand fusion protein and the vaccine, and relates to the technical field of vaccines, the antigen-ligand fusion protein comprises a first structural unit and a second structural unit, the first structural unit is a virus antigen, and the second structural unit is a CD91 ligand. The antigen-ligand fusion protein provided by the invention can provide a strong and lasting antibody level for an organism.

The present disclosure relates to the expression of recombinant viral antigens using transgenic fungi. Compositions, production and administration of vaccines comprising those viral antigens are also disclosed. In some embodiments, these viral antigens can be used to formulate vaccines against Newcastle disease. These vaccines may be administered, for example, by intramuscular injection.

The present disclosure provides a polyribonucleotide encoding a polypeptide that comprises a viral antigen from Herpes Simplex Virus-2 (HSV-2); for example, the viral antigen comprises the ectodomain of HSV-2 glycoprotein B. The polyribonucleotide can be formulated as an RNA composition useful for inducing anti-HSV immune responses in a subject.

The invention discloses preparation and application of porcine reproductive and respiratory syndrome virus circular RNA (Ribonucleic Acid) and a vaccine. The circular RNA encodes and expresses GP5 protein optimized by the porcine reproductive and respiratory syndrome virus and M protein optimized by the porcine reproductive and respiratory syndrome virus. The optimized circular RNA molecule is prepared into a vaccine to successfully induce a high-level neutralizing antibody in a pig body, so that the proportion of CD4 + IFN-gamma + and CD8 + IFN-gamma + cells in PBMC cells is remarkably increased, the lymphocyte proliferation activity after specific stimulation of a virus antigen is remarkably improved, and the protection of the porcine reproductive and respiratory syndrome virus is effectively realized. The invention provides a basis for preparing the RNA vaccine for preventing and / or treating the porcine reproductive and respiratory syndrome virus.

The invention discloses an anti-porcine epidemic diarrhea virus monoclonal antibody and application thereof. The anti-porcine epidemic diarrhea virus monoclonal antibody comprises a monoclonal antibody 2D14 or an antigen binding fragment thereof, and a monoclonal antibody 8F17 or an antigen binding fragment thereof. The two monoclonal antibodies can be combined with PEDV fusion protein with high affinity, have no cross reaction with other common porcine enterovirus antigens, are good in specificity, can construct a stable double-antibody sandwich immunochromatography system, are simple and convenient to operate, high in detection sensitivity, low in background and rapid in reaction, can develop color within 10-15 minutes, and can be applied to detection of porcine enteroviruses. Clear interpretable signals can be generated for a plurality of subtype samples of PEDV, the result can be interpreted by naked eyes, the detection result is stable, the repeatability is good, and the kit is suitable for on-site rapid detection and clinical application.

The invention provides a joint detection test strip for dengue virus and Zika virus antigens and antibodies and a preparation method of the joint detection test strip. According to the combined detection test strip, the combined detection test strip with the dengue virus NS1 antigen and the dengue virus IgG / IgM antibody adopts a multi-site recombinant antigen labeling or multi-site recombinant antibody coating form, so that the sensitivity of a reagent is improved; the problems of poor specificity and release residue of latex microspheres are solved by optimizing the confining liquid; colored latex microspheres are used as a marker, a detection target is more intuitively distinguished according to line colors, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is more quickly improved, and the dengue virus NS1, the Zika virus NS1 antigen, the dengue virus IgG / IgM antibody and the Zika virus IgG / IgM antibody can be detected at the same time; and the kit is convenient to carry, simple to operate, convenient for on-site instant detection and capable of performing large-scale preliminary screening.

The present invention relates to a novel vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). According to the invention, after the SFTSV vaccine is injected in vivo, the formation speed of Gn and Gc proteins can be obviously accelerated. Besides, the vaccine can effectively stimulate humoral immune response, for example, a specific neutralizing antibody aiming at a virus antigen is induced to generate, so that a remarkable protection effect aiming at SFTSV is provided for an individual.

The invention provides a novel ecological feed capable of preventing multiple grass-bream diseases, the novel ecological feed comprises a feed matrix and an ecological feed leavening agent, and the ecological feed leavening agent comprises probiotics with surface expression antigens, the antigen is any one or more of a grass carp reovirus antigen, a flavobacterium johnsonii antigen, an aeromonas veronii antigen and a clonorchis sinensis antigen. The novel ecological feed with a disease-resistant function in a parabramis pekinensis breeding mode is prepared for the first time, the resistance of the parabramis pekinensis to various pathogens can be enhanced, and the survival rate of the parabramis pekinensis in the disease attack peak period can be increased by 50% or above after immunization. An oral immunization mode is adopted and can be completed in the feeding process, and the immunization and breeding cost is greatly saved.

The present invention relates to a recombinant vaccine comprising a PIV5-based viral expression vector with a genetic insert, and methods of producing and using the same. The recombinant vaccine comprises a modified bacterial or viral antigen to increase expression of the antigen on the surface of cells (AOS) to increase immunogenicity to the antigen.

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

The invention belongs to the technical field of biological medicine, and discloses an aquatic animal antigen system and application thereof. The preparation method comprises the following steps: carrying out carboxylation treatment on bacterial cellulose to prepare carboxylated bacterial nano-cellulose, and then carrying out grafting reaction on the carboxylated bacterial nano-cellulose and an aldehyde group polymer to prepare surface modified nano-cellulose (namely poly (N-isopropylacrylamide) grafted carboxylated bacterial nano-cellulose). The surface-modified nanocellulose is used as a carrier and is chemically connected with a virus antigen protein (namely recombinant G protein) to prepare an antigen system (namely BNC-G) carrying the virus antigen protein. According to the antigen system, virus antigen protein can be delivered into aquatic animal bodies through soaking immunization, the effect of preventing and controlling aquatic animal virus diseases is achieved, and the antigen system is suitable for production of aquatic animal SPF seedlings and preparation of aquatic animal immune protection preparations.

The present invention provides a method for culturing immune organoids and its application. The present invention cultures immune organoids by isolating lung-infiltrating lymph nodes and evaluates the level of mucosal immune response produced against influenza virus. By adding components such as BAFF and IL-2 to the cell culture medium and using the air-liquid interface method to three-dimensionally reconstruct immune cells derived from lung-infiltrating lymph nodes, immune organoids with a lymphoid structure are formed. These immune organoids can more realistically reflect the level of local immune response in the lungs and better retain various immune cells. At the same time, T cells are activated, enhancing their helper effect on B cells; the time for B cells to differentiate into plasma cells and mature is greatly shortened, and the efficiency of detecting and evaluating the immunogenicity of viral antigens is improved.

The application discloses a live vaccine heat-resistant protective agent and a preparation method and application thereof, which is composed of the following components in mass volume percentage: 3-5% of glucose, 1-3% of thiourea, 5-8% of lactose, 0.5-1% of ascorbic acid, 1-3% of glycine, 0.5-1% of poloxamer 188, 1-2% of povidone K30, 3-6% of tert-butyl alcohol, and the balance is water for injection. The application has simple components, easily available raw materials and simple preparation method, can effectively reduce the loss of virus antigens in the freeze-drying process when the live vaccine for small ruminant pestivirus is prepared, and can ensure the immunization efficacy and long-term stable storage of the live vaccine for small ruminant pestivirus.

Provided herein are novel chimeric polypeptides that bind to antigen peptides (e.g., viral antigens or tumor associated antigens) and activate the endogenous phagocytosis signaling pathway. Also provided are compositions and methods for producing such chimeric polypeptides, nucleic acids encoding such chimeric polypeptides, phagocytes that have been modified to express such chimeric polypeptides, and methods for treating various conditions, such as viral infections or cancer.

The present disclosure provides a type A foot-and-mouth disease virus-like particle antigen assembled by VP2, VP3 and VP1 antigen proteins of an epidemic strain of type A foot-and-mouth disease virus. The type A foot-and-mouth disease virus VP2 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 1 or its degenerate sequence, the type A foot-and-mouth disease virus VP3 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 2 or its degenerate sequence, and the type A foot-and-mouth disease virus VP1 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 3 or its degenerate sequence.

The present invention relates to the field of vaccinology, more particularly to the field of veterinary vaccinology. In particular, the present invention relates to an adjuvant composition comprising an emulsion of water, tocopherol or a pharma- ceutically acceptable ester thereof, and polyethoxyethylene cetostearyl ether as an emulsifier. This adjuvant composition can be used to formulate a vaccine, in particular an emulsion vaccine, comprising a bacterial, parasitic or viral antigen. The resulting vaccine composition can be used in a method for protecting a human or animal subject from infection and / or disease caused by a pathogen, in particular caused by a bacterium, a parasite or a virus. The present invention further relates to a method for producing such an adjuvant composition and a method for producing such a vaccine composition.

The present invention relates to a composition comprising a self-amplifying RNA (saRNA) encoding at least one polypeptide of infectious laryngotracheitis virus (ILTV; Gallid alphaherpesvirus 1, GaHV-1), a polypeptide variant of ILTV, or an immunogenic fragment or epitope thereof, and a pharmaceutically acceptable excipient comprising lipid inorganic nanoparticles (LION).More specifically, the sRNA encodes at least one laryngotracheitis virus polypeptide, an ILTV polypeptide variant, or an immunogenic fragment or epitope thereof, said sRNA comprising a first nucleic acid sequence including nsP1, nsP2, nsP3 and nsP4 which encode non-structural alphavirus proteins, a second nucleic acid sequence encoding at least one ILTV polypeptide, an ILTV polypeptide variant, an immunogenic fragment or an epitope thereof, and also comprising a 5' cap, a 5' UTR upstream of the first nucleic acid sequence, a 26S promoter upstream of the second nucleic acid sequence, a 3' UTR and a poly A tail.

The present disclosure provides a polyribonucleotide encoding a polypeptide comprising a viral antigen from herpes simplex virus-2 (HSV-2); for example, the viral antigens comprise an extracellular domain of HSV-2 glycoprotein B. The polyribonucleotides can be formulated as RNA compositions that can be used to induce an anti-HSV immune response in a subject.

To provide a novel chimeric antigen receptor-T cell (CAR-T cell) therapy, and to provide a medicament using the same.SOLUTION: Provided are: a method for producing T cell-derived induced Pluripotent Stem Cells (T-iPSCs) with two antigen receptors, comprising introducing, into cytotoxic T lymphocyte (CTL)-derived iPS cells (T-iPSCs) specific to a tumor antigen or viral antigen expressed on target cells, a chimeric antigen receptor (CAR) specific for an antigen different from the antigen; T-iPSCs with a T cell receptor (TCR) specific to a tumor antigen or viral antigen expressed on target cells and a CAR specific to an antigen different from the antigen; and furthermore, CTLs expressing a TCR specific to a tumor antigen or viral antigen expressed on target cells and a CAR specific to an antigen different from the antigen.SELECTED DRAWING: None

The present invention relates to a nucleic acid molecule encoding a multispecific antigen-binding protein and exhibiting significantly improved expression efficiency in vivo. In the multispecific antigen-binding protein of the present invention, specifically, a bispecific antibody that recognizes a tumor antigen or a viral antigen and a natural killer cell-specific activating receptor, the light chain variable region (VL) and the heavy chain variable region (VH) of a receptor-recognizing site of a natural killer cell-specific activating receptor are sequentially arranged in the N-terminus to the C-terminus direction, thereby increasing expression efficiency by up to 8-fold. Therefore, the present invention provides an optimal mRNA structure capable of most efficiently expressing bispecific antibodies in vitro and in vivo, thereby enabling effective use thereof for not only mass-production of recombinant bispecific antibodies but also as an excellent mRNA therapeutic agent for stable and continuous production of a therapeutically effective amount of bispecific antibodies in the body of a patient.

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.

The present invention provides an immunogenic composition comprising recombinant peptides and proteins, the recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSV F protein peptides. The immunogenic composition comprises a secreted fusion protein comprising a soluble RSV viral antigen, which is linked to the collagen C-terminal portion by in-frame fusion to form a disulfide-linked trimeric fusion protein. The immunogenic composition can be used to generate an immune response, such as for treating or preventing RSV infection. The immunogenic composition can be used in vaccine compositions, such as as part of a preventive and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prevention, treatment and / or diagnostic methods, and related kits.

Immunogenic compositions and methods of use thereof, for eliciting an immune response against one or more virally driven cancers are described. The compositions typically include one or more viral antigens expressed in the virally driven cancers, or a nucleic acid encoding the same, and optionally one or more adjuvants. Preferably, the compositions include nucleic acids (e.g., mRNA) encoding one or more viral antigens. Exemplary antigens include those derived from a truncated form of the viral Large T Antigen (LTA) or Small T Antigen (STA) of Merkel Cell Polyomavirus (MCPyV), or E2, E5, or E6 proteins of HPV. Pharmaceutical compositions and dosages including one or more of the compositions and an excipient, and methods of immunizing subjects and priming and engineer T cells for use in adoptive therapy are also provided.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The invention discloses an F1 monoclonal antibody and application thereof, the F1 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the F1 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of the VHCDR1, the VHCDR2 and the VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of the VLCDR1, the VLCDR2 and the VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses an application of the F1 monoclonal antibody. The F1 monoclonal antibody can neutralize SARS-CoV-2 virus infection, and has important application value in serological detection of new coronavirus, preparation of a reagent for new coronavirus infection detection and a reagent for new coronavirus antigen or antibody detection.

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

The present invention relates to a method for determining the presence and / or amount of human IgG3 antibodies, preferably specific for a viral antigen, in a sample. The present invention also relates to the use of said method in the quality control of viral vaccines and in the diagnosis of viral infections. Furthermore, a kit for use in said method is described.

The utility model provides a kind of virus antigen rapid detection test paper, it is related to biological detection technical field, multi-dimensional gradient compound synergistic component, integrate dendritic flow guide groove and nano microporous structure on sample pad, it can promote processing liquid and sample to be radially evenly distributed in diffusion process, on the one hand, effectively avoid the detection interference caused by local liquid concentration too high, on the other hand, significantly shorten the liquid infiltration time of detection starting stage, improve chromatography efficiency, set up gradient distribution's antigen line on NC membrane, its virus specificity antigen concentration is increasing distribution from the end close to binding pad to bibulous pad, accurately adapt the detection requirement of different virus load sample, low virus load sample because of less combined compound, can flow to bibulous pad end high concentration antigen area sufficient combination and produce strong signal, avoid missed detection, high virus load sample because of compound sufficiency, preferentially and binding pad end low concentration antigen area quickly combine, effectively avoid signal inhibition or false negative problem.

The invention relates to a fusion protein GLuc-p30 and a preparation method and application thereof. With p30 protein of African swine fever as a diagnostic antigen, an African swine fever antibody detection method based on a luciferase immunoprecipitation system is established. In the method, a fusion antigen of luciferase and p30 is prepared by DNA transfection of eukaryotic cells, the antigen is secreted outside the cell, the fusion antigen is combined with African swine fever antibodies in a serum sample, and then captured by magnetic beads coupled with Staphylococcus aureus protein A, and the fusion antigen specifically combined with the magnetic beads is detected by a luciferase test; the virus antigen expressed by the eukaryotic cells used in the invention contains post-translational modifications such as phosphorylation, is closer to the virus protein expressed under infection, and does not need to be purified, thereby simplifying the preparation process of the antigen; compared with the existing indirect ELISA, the detection method of the invention has better detection sensitivity and specificity; the detection method of the invention has the advantages of simplicity, sensitivity, specificity, low price, etc., and can meet the requirements of large-scale detection.